Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776273 | 0.90 | FAAH (0.36) | GAAFAAHKMT2ADYRK1ANPC1 | |
| SCHEMBL17618744 | 0.90 | GRM5 (0.47) | FAAHKMT2ASIRT2KARS1RAB9A | |
| SCHEMBL20631481 | 0.90 | GAA (0.38) | GAAFAAHKMT2ASIRT2KARS1 | |
| SCHEMBL16776256 | 0.90 | GRM5 (0.40) | FAAHSIRT2KARS1DYRK1ARAB9A | |
| SCHEMBL16776262 | 0.88 | FAAH (0.39) | FAAHKMT2AKDM4ECA9KMO | |
| SCHEMBL16776205 | 0.87 | TSHR (0.46) | FAAHKMT2AKDM4ECA9KMO | |
| SCHEMBL19699090 | 0.86 | DYRK1A (0.42) | KARS1DYRK1ACA9GSK3B | |
| SCHEMBL17778903 | 0.85 | FAAH (0.35) | GAAFAAHKMT2ADYRK1ANPC1 | |
| SCHEMBL16754331 | 0.85 | FAAH (0.35) | GAAFAAHKMT2ADYRK1ANPC1 | |
| SCHEMBL17618424 | 0.85 | GRM5 (0.44) | FAAHKMT2ASIRT2KARS1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GAA 1368/4885FAAH 977/4885KMT2A 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.